Molbio's proprietary test kits accounted for most product revenue in FY26, while unused manufacturing capacity offers room to grow. Government procurement cycles, overseas expansion and the company's valuation remain key factors to watch.
Molbio's proprietary test kits accounted for most product revenue in FY26, while unused manufacturing capacity offers room to grow. Government procurement cycles, overseas expansion and the company's valuation remain key factors to watch.
<iframe src="https://hindustansphere.com/embed/cluster/3de0caf9a3bd630d5b6a5c1addac786cb09a80cc" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Molbio Diagnostics Has Spare Capacity. Can It Turn That Into Growth?"></iframe>
